Persistence of Mycoplasma genitalium Following Azithromycin Therapy
Open Access
- 3 November 2008
- journal article
- clinical trial
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (11) , e3618
- https://doi.org/10.1371/journal.pone.0003618
Abstract
To determine clinical outcomes and cure rates for M.genitalium genital infection in men and women following azithromycin 1 g. Patients attending Melbourne Sexual Health Centre between March 2005 and November 2007 with urethritis/epididymitis, cervicitis/pelvic inflammatory disease and sexual contacts of M.genitalium were tested for M.genitalium by polymerase chain reaction (PCR). M.genitalium-infection was treated with 1 g of azithromycin and a test-of-cure (toc) was performed one month post-azithromycin. Response to azithromycin, and response to moxifloxacin (400 mg daily for 10 days) in individuals with persistent infection post-azithromycin, was determined. Of 1538 males and 313 females tested, 161 males (11%) and 30 females (10%) were infected with M.genitalium. A toc was available on 131 (69%) infected individuals (median = 36 days [range 12-373]). Of 120 individuals prescribed azithromycin only pre-toc, M.genitalium was eradicated in 101 (84%, 95% confidence intervals [CI]: 77–90%) and persisted in 19 (16%, 95% CI: 10–23%). Eleven individuals with persistent infection (9%, 95% CI: 5–15%) had no risk of reinfection from untreated-partners, while eight (7%, 95% CI: 3–12%) may have been at risk of reinfection from doxycycline-treated or untreated-partners. Moxifloxacin was effective in eradicating persistent infection in all cases not responding to azithromycin. Patients with persistent-M.genitalium were more likely to experience persistent symptoms (91%), compared to patients in whom M.genitalium was eradicated (17%), pM.genitalium-infected patients was associated with unacceptable rates of persistent infection, which was eradicated with moxifloxacin. These findings highlight the importance of follow-up in M.genitalium-infected patients prescribed azithromycin, and the need to monitor for the development of resistance. Research to determine optimal first and second-line therapeutic agents for M.genitalium is needed.Keywords
This publication has 20 references indexed in Scilit:
- Azithromycin Failure inMycoplasma genitaliumUrethritisEmerging Infectious Diseases, 2006
- Intrastrain Heterogeneity of the mgpB Gene in Mycoplasma genitalium Is Extensive In Vitro and In Vivo and Suggests that Variation Is Generated via Recombination with Repetitive Chromosomal SequencesInfection and Immunity, 2006
- Sequence-Based Typing of Mycoplasma genitalium Reveals Sexual TransmissionJournal of Clinical Microbiology, 2006
- Detection of Mycoplasma genitalium in women with laparoscopically diagnosed acute salpingitisSexually Transmitted Infections, 2005
- Antibiotic Susceptibility Testing of Mycoplasma genitalium by TaqMan 5′ Nuclease Real-Time PCRAntimicrobial Agents and Chemotherapy, 2005
- In Vitro Activity of Fluoroquinolones against Mycoplasma genitalium and Their Bacteriological Efficacy for Treatment of M. genitalium-Positive Nongonococcal Urethritis in MenClinical Infectious Diseases, 2005
- Tetracycline treatment does not eradicate Mycoplasma genitaliumSexually Transmitted Infections, 2003
- Quantitative Detection of Mycoplasma genitalium from First-Pass Urine of Men with Urethritis and Asymptomatic Men by Real-Time PCRJournal of Clinical Microbiology, 2002
- Comparative Susceptibilities of Various Aids-Associated and Human Urogenital Tract Mycoplasmas and Strains of Mycoplasma Pneumoniae to 10 Classes of Antimicrobial Agent In VitroJournal of Medical Microbiology, 1998
- Molecular Amplification Assays to Detect Chlamydial Infections in Urine Specimens from High School Female Students and to Monitor the Persistence of Chlamydial DNA after TherapyThe Journal of Infectious Diseases, 1998